MAVER (REDMESIVIR)
Information of COVID-19 virun MAVER (REMDESIVIR) 1.AUTHORIZES USE Maver (Remdesivir) is authorized for use under an EUA for Vestment of patients hospitalized with suspected or laboratory confirmed SARS-CoV-2 infection and severe disease. Severe disease is defined as patients with oxygen saturation (Sp021594% on room air or requiring supplemental oxygen or requiring mechanical ventilation or requiring extracorporeal membrane oxygenation (ECM()) Specifically Mover (Remdesivir) is only authorized for hospitalized adult and pediatric patients for whom use of an intravenous agent is clinically appropriate. 2. DOSAGE AND ADMINISTRATION 2.1- General Information The optimal dosing and duration of treatment is unknown. The suggested dose and duration may be updated as data from clinical trials becomes available · Adult and pediatnc patients (>28 days old) must have an eGFR determined and full-term neonates (27 days to 528 days old) must have serum creatinine determine
